Pacer Advisors’s TG Therapeutics TGTX Stock Holding History

Pacer Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54K	Buy	+989	New	+$40.5K	﹤0.01%	2020
2024 Q4	–	Sell	-11,863	Closed	-$277K	–	3728
2024 Q3	$277K	Buy	11,863 +9,946	+519%	+$217K	﹤0.01%	1781
2024 Q2	$34.1K	Sell	1,917 -625	-25%	-$9.97K	﹤0.01%	3312
2024 Q1	$38.7K	Buy	+2,542	New	+$40.5K	﹤0.01%	3272
2021 Q2	–	Sell	-1,562	Closed	-$75K	–	1554
2021 Q1	$75K	Sell	1,562 -1,568	-50%	-$75.3K	﹤0.01%	1346
2020 Q4	$163K	Sell	3,130 -2,988	-49%	-$101K	﹤0.01%	1268
2020 Q3	$164K	Buy	+6,118	New	+$141K	﹤0.01%	1206
2018 Q4	–	Sell	-10,626	Closed	-$60K	–	993
2018 Q3	$60K	Buy	+10,626	New	+$121K	﹤0.01%	1133
2018 Q1	–	Sell	-3,425	Closed	-$28K	–	1127
2017 Q4	$28K	Buy	+3,425	New	+$29.9K	﹤0.01%	1075

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pacer Advisors's TGTX Position: Q2 2026 in Review

Pacer Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 989 shares worth $54K. The stake represents ﹤0.01% of the portfolio and ranks #2020 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in TGTX as recently as Q3 2024.

Pacer Advisors first reported a position in TGTX in Q4 2017 and has held it in 9 quarters since. The position peaked at $277K in Q3 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Pacer Advisors held 989 shares of TG Therapeutics worth $54K as of Q2 2026.
TG Therapeutics was a new Pacer Advisors position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2020 holding.
Pacer Advisors first reported a position in TG Therapeutics in Q4 2017 and has held it in 9 quarters since.
Pacer Advisors's TG Therapeutics position peaked at $277K in Q3 2024.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.